American Society for Investigative Pathology

American Society for Investigative Pathology

The Pathologist and the Development of Targeted Therapies

Session Credits: 3 CME and 3 SAMs

Sunday, March 13, 2016
1:30 PM- 5:00 PM

Moderators: Maria J. Merino, MD, National Cancer Institute, Bethesda, MD
Danny A. Milner, MD, MSc, Brigham and Women’s Hospital, Boston, MA
Mark E. Sobel, MD, PhD, American Society for Investigative Pathology, Bethesda, MD

Course Description:
The integration of anatomic, molecular, and genomic pathology into surgical pathology practice is conspicuous in oncology, where definition of molecular pathways important for specific tumors has enabled development of drugs and innovative immunological approaches to target these pathways, and companion tests to predict which tumors are likely to respond to these targeted agents. The role of the surgical pathologist as part of the oncologic healthcare team is rapidly evolving. This session will focus on targeted therapies for melanoma and cancers of the brain, breast, and lung.

Upon completion of this activity, participants should be better able to:

1. Describe the new morphologic and molecular classification scheme of gliomas.
2. Describe approaches to cancer immunotherapies.
3. Describe immune targeting in breast cancer.
4. Describe the evolving molecular classification of lung cancer.

Agenda